• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Akumin Inc.

    11/14/23 4:40:16 PM ET
    $AKU
    Medical Specialities
    Health Care
    Get the next $AKU alert in real time by email
    NT 10-Q 1 form12b-2511142023.htm NT 10-Q Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549


    FORM 12b-25

    NOTIFICATION OF LATE FILING

    (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☑ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

    For Period Ended: 9/30/2023
    ☐ Transition Report on Form 10-K
    ☐ Transition Report on Form 20-F
    ☐ Transition Report on Form 11-K
    ☐ Transition Report on Form 10-Q
    For the Transition Period Ended:

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.
    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:


    PART I — REGISTRANT INFORMATION

    Akumin Inc.                             
    Full Name of Registrant

                                         
    Former Name if Applicable

    8300 W Sunrise Blvd.                         
    Address of Principal Executive Office (Street and Number)
    Plantation, Florida 33322                         
    City, State and Zip Code

    PART II — RULES 12b-25(b) AND (c)

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
    12b-25(b), the following should be completed. (Check box if appropriate)
    (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☐
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.


    SEC 1344 (06-19)
    Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.





    PART III — NARRATIVE
    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion
    thereof, could not be filed within the prescribed time period.

    (Attach extra Sheets if Needed)

    PART IV — OTHER INFORMATION

    (1) Name and telephone number of person to contact in regard to this notification

            David Kretschmer                844                730-0050    

    (Name) (Area Code) (Telephone Number)

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☑ Yes ☐ No



    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☑ No
    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.


                                Akumin Inc.                        
    (Name of Registrant as Specified in Charter)

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

    Date November 14, 2023 By /s/ David Kretschmer
    Chief Financial Officer

    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

    ATTENTION
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).


    GENERAL INSTRUCTIONS

    1.This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange Act of 1934.

    2.One signed original and four conformed copies of this form and amendments thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act. The information contained in or filed with the form will be made a matter of public record in the Commission files.

    3.A manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any class of securities of the registrant is registered.

    4.Amendments to the notifications must also be filed on Form 12b-25 but need not restate information that has been correctly furnished. The form shall be clearly identified as an amended notification.

    5.Interactive data submissions. This form shall not be used by electronic filers with respect to the submission or posting of an Interactive Data File (§232.11 of this chapter). Electronic filers unable to submit or post an Interactive Data File within the time period prescribed should comply with either Rule 201 or 202 of Regulation S-T (§232.201 and §232.202 of this chapter).

    2



    Form 12B-25
    Part III - Narrative
    Part III — Narrative
    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

    Akumin Inc. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Form 10-Q”) by the prescribed due date for the reasons further described below.

    As previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on October 16, 2023, the Company determined on October 11, 2023 that its information technology network was affected by ransomware. Upon becoming aware, the Company took quick action to secure its networks, including shutting down systems.
    As such, certain systems and functionalities used in financial reporting were not available for a period of time. As a result, the Company is unable to complete and file the Form 10-Q by the prescribed due date without unreasonable effort and expense. As previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on November 2, 2023, the Company had then restored the majority of its systems. The Company intends to file the Form 10-Q as soon as practicable and currently anticipates filing the Form 10-Q on or before December 15, 2023; however, there can be no assurance with respect to the timing of completion of the filing.

    This Form 12b-25 includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the timing of the filing of the Form 10-Q. All statements, other than statements of historical fact, contained in this Form 12b-25 are forward-looking statements. Forward-looking statements contained in this Form 12b-25 may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company’s control and which could materially affect results.

    Factors that could cause actual results to differ materially from such forward-looking statements include, but are not limited to, the following: additional information regarding the extent of the ransomware incident that the Company may uncover during its ongoing investigation; the Company’s ability to assess and remedy the incident; the Company’s ability to service its customers following the incident; the compromise or improper use of sensitive, proprietary, confidential financial, or personal data or information resulting in negative consequences such as fines, penalties, or loss of reputation, competitiveness or customers; incremental expenses associated with the Company’s on-going assessment of the incident; the nature and scope of any claims, litigation or regulatory proceedings that may be brought against the Company or other affected parties as a result of the incident; the availability of insurance coverage; other legal, reputational and financial risks resulting from this or other ransomware incidents and the potential impact of this incident on the Company’s revenues, operating expenses, and operating results; and the length and scope of disruptions to the Company’s business operations caused by the incident. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company’s most recent Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, as well as any amendments thereto reflected in subsequent filings with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this Form 12b-25 speak only as of the date hereof, and, except as required by law, the Company undertakes no duty or obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


    Get the next $AKU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKU

    DatePrice TargetRatingAnalyst
    11/14/2022$3.50 → $3.00Buy → Speculative Buy
    Canaccord Genuity
    More analyst ratings

    $AKU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Akumin downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Akumin from Buy to Speculative Buy and set a new price target of $3.00 from $3.50 previously

    11/14/22 8:59:34 AM ET
    $AKU
    Medical Specialities
    Health Care

    $AKU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Foursixthree Capital Lp claimed ownership of 10,556,851 shares (SEC Form 3)

    3 - AKUMIN INC. (0001776197) (Issuer)

    2/5/24 4:50:02 PM ET
    $AKU
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Bienias Ronald J.

    3 - AKUMIN INC. (0001776197) (Issuer)

    10/26/23 10:40:46 AM ET
    $AKU
    Medical Specialities
    Health Care

    SEC Form 4 filed by Kumar Krishna

    4 - AKUMIN INC. (0001776197) (Issuer)

    7/18/23 1:31:57 PM ET
    $AKU
    Medical Specialities
    Health Care

    $AKU
    SEC Filings

    View All

    $AKU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SEC Form EFFECT filed by Akumin Inc.

    EFFECT - AKUMIN INC. (0001776197) (Filer)

    2/13/24 12:15:09 AM ET
    $AKU
    Medical Specialities
    Health Care

    SEC Form 15-12G filed by Akumin Inc.

    15-12G - AKUMIN INC. (0001776197) (Filer)

    2/7/24 6:11:57 AM ET
    $AKU
    Medical Specialities
    Health Care

    SEC Form S-8 POS filed by Akumin Inc.

    S-8 POS - AKUMIN INC. (0001776197) (Filer)

    2/7/24 6:09:57 AM ET
    $AKU
    Medical Specialities
    Health Care

    Akumin Announces Changes to Leadership Team

    Krishna Kumar, Current President & Chief Operating Officer, Appointed Chief Executive Officer Chandra Westergaard Named General Counsel PLANTATION, Fla., Feb. 8, 2024 /CNW/ - Akumin Inc. ("Akumin" or the "Company") announced today that Krishna Kumar, who has served as President and Chief Operating Officer at the Company, has been appointed Chief Executive Officer, effective immediately. He succeeds Riadh Zine, Akumin's Founder, who is stepping down as Chairman and Chief Executive Officer. Akumin also announced that Chandra Westergaard has been named General Counsel and will oversee the Company's legal and compliance functions. "On behalf of Akumin, I would like to thank Riadh for his dedica

    2/8/24 5:00:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    Akumin Inc. Completes Deleveraging Transaction, Becomes a Private Company Wholly-Owned by Stonepeak

    Akumin well-positioned to continue providing top-quality radiology and oncology services to patients, health systems, hospitals, and physician groups across the U.S. PLANTATION, Fla., Feb. 6, 2024 /CNW/ - Akumin Inc. ("Akumin" or the "Company") today announced that it has completed its deleveraging transaction, becoming a private company wholly-owned by Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets. The deleveraging and recapitalization transaction was implemented through a voluntary, court-supervised financial restructuring process, which is now complete. "We are pleased to have concluded this process and are excited to enter our next chapt

    2/6/24 6:26:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    Akumin Inc. Provides Update on its Restructuring Transaction

    /NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/  PLANTATION, Fla., Jan. 31, 2024 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its previously announced restructuring transaction involving Stonepeak as well as its bondholders, lenders, shareholders and other stakeholders under a prepackaged chapter 11 plan of reorganization (the "Prepackaged Plan") is expected to become effective on or around February 6, 2024 (the "Effective Date"), subject to satisfaction of all of the remaining conditions to the closing of the restructuring transaction. On

    1/31/24 10:26:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    $AKU
    Financials

    Live finance-specific insights

    View All

    Akumin Inc. Provides Update on its Restructuring Transaction

    /NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/  PLANTATION, Fla., Jan. 31, 2024 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its previously announced restructuring transaction involving Stonepeak as well as its bondholders, lenders, shareholders and other stakeholders under a prepackaged chapter 11 plan of reorganization (the "Prepackaged Plan") is expected to become effective on or around February 6, 2024 (the "Effective Date"), subject to satisfaction of all of the remaining conditions to the closing of the restructuring transaction. On

    1/31/24 10:26:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    Akumin Announces Second Quarter 2023 Results, Revised FY23 Financial Outlook and Establishment of Special Committee

    PLANTATION, Fla., Aug. 9, 2023 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company"), a national partner of choice for U.S. hospitals, health systems and physician groups, with comprehensive solutions addressing outsourced radiology and oncology service-line needs, announced today its financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Akumin delivered second quarter same-store volume performance on a consolidated basis as follows:+3.1% for MRI+16.5% for PET/CT+3.4% for Oncology Patient StartsThe Company reported revenue totaling $184.8 million for the second quarter, a $7.3 million or 4% decrease over the second quarter of last year.

    8/9/23 5:23:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    Akumin to Host Second Quarter 2023 Financial Results Call on August 10, 2023

    PLANTATION, Fla., Aug. 8, 2023 /PRNewswire/ - Akumin Inc. (TSX:AKU) ("Akumin" or the "Company") will host a conference call at 8:30 a.m. Eastern Time, Thursday, August 10, 2023, to discuss its second quarter 2023 financial results.  The financial results are expected to be available on Wednesday, August 9, 2023. To access the conference call, participants may join by using an appropriate dial-in number available through https://akum.in/Q2-2023-Results-Dial-In-Numbers or via webcast at https://akum.in/Q2-2023-Results-Webcast. A related presentation will be available from Akumin's website (www.akumin.com). Participants are asked to connect at least 10 minutes prior to the beginning of the call

    8/8/23 5:23:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    $AKU
    Leadership Updates

    Live Leadership Updates

    View All

    AKUMIN ANNOUNCES LEADERSHIP TRANSITION

    PLANTATION, Fla., Dec. 29, 2023 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its Board of Directors has appointed Ronald J. Bienias, Akumin's Chief Restructuring Officer and Partner and Managing Director of AlixPartners, LLP, as Interim Chief Financial Officer, effective today. He will also maintain his current role as Chief Restructuring Officer. Ronald's appointment follows the resignation of David Kretschmer, as Akumin's Chief Financial Officer effective today. Ronald has more than 20 years of experience serving in interim leadership roles or as an advisor at both large and

    12/29/23 7:52:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    Akumin Announces Change of Auditor

    PLANTATION, Fla., Aug. 9, 2023 /PRNewswire/ - Akumin Inc. ("Akumin" or the "Company") (NASDAQ:AKU) (TSX:AKU) announced today that it has changed its auditor from Ernst & Young LLP ("EY") to Deloitte & Touche LLP ("Deloitte"). Effective as of August 9, 2023, the audit committee (the "Audit Committee") of the board of directors (the "Board") of the Company dismissed EY as the Company's independent registered public accounting firm. EY audited the Company's financial statements for each of the past two fiscal years ended December 31, 2022 and 2021, and EY's reports did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or

    8/9/23 5:31:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    Akumin appoints President and Chief Operating Officer

    PLANTATION, Fla., June 12, 2023 /CNW/ - Akumin Inc. ("Akumin" or the "Company") (NASDAQ:AKU) (TSX:AKU) today announced the appointment of Krishna Kumar as President and Chief Operating Officer of the Company, effective as of June 16, 2023. Krishna has valuable experience and exceptional insight into the radiology space, having served as Senior Vice President & Business Leader - Precision Diagnosis at Philips North America, where he built a top performing team and business, over the last four years. Prior to this role, he led global businesses in Pathology, Oncology and Neuro at Philips based in Amsterdam, Netherlands from 2015-2019 and prior thereto was the CEO of Philips India. Before joini

    6/12/23 6:59:57 AM ET
    $AKU
    Medical Specialities
    Health Care

    $AKU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Akumin Inc. (Amendment)

    SC 13G/A - AKUMIN INC. (0001776197) (Subject)

    2/12/24 4:37:41 PM ET
    $AKU
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Akumin Inc.

    SC 13G - AKUMIN INC. (0001776197) (Subject)

    2/12/24 4:31:27 PM ET
    $AKU
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Akumin Inc. (Amendment)

    SC 13G/A - AKUMIN INC. (0001776197) (Subject)

    2/7/24 10:43:55 AM ET
    $AKU
    Medical Specialities
    Health Care